Key facts
- InnoGene BioTech’s last known valuation is $27.0M (Dec 2022).
- It has raised $41.5M; the latest was Early Stage VC ($20.6M) in Mar 2025.
- Notable investors include Hefei Industry Investment Group, Furong Capital, Flyfot Ventures, Fontus Capital, Hangzhou Huaiji Investment — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for InnoGene BioTech
- ·The full record, as it builds
Funding rounds
No funding rounds for InnoGene BioTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnoGene BioTech
Developer of green synthetic biological products. This company's products are based on a synthetic biology platform with technologies in component mining, strain modification and screening, fermentation optimization, and has developed several proven metabolic pathways for chassis cells, providing ustomers in the fields of natural flavors, nutritional health, and biopharmaceuticals with products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
InnoGene BioTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnoGene BioTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnoGene BioTech in its N-PORT filings yet. We sweep new filings monthly.